alpha smooth muscle actin αsma (Proteintech)
Proteintech is a verified supplier 
96
Structured Review
Proteintech
alpha smooth muscle actin αsma
Alpha Smooth Muscle Actin αsma, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1237 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alpha+smooth+muscle+actin+polyclonal+antibody/smooth+muscle+actin+Polyclonal+antibody/10__3390_slash_ijms27052432-138-7-15
Average 96 stars, based on 1237 article reviews
Alpha Smooth Muscle Actin αsma, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1237 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alpha+smooth+muscle+actin+polyclonal+antibody/smooth+muscle+actin+Polyclonal+antibody/10__3390_slash_ijms27052432-138-7-15
Average 96 stars, based on 1237 article reviews
alpha smooth muscle actin αsma - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
other:Article Title: Qizhu Rougan Granules suppress liver fibrosis by inhibiting the expression of the P2Y14 receptor on hepatic stellate cells Article Snippet: The primary antibodies of the experiment are P2Y14 Polyclonal Antibody (PA5-96964, Invitrogen, United States), Article Title: Curcumenol exerts anti-pulmonary fibrosis effects through modulation of the immune signature target SPP1: based on comprehensive bioinformatics and experiments validation. Article Snippet: Background: The efficacy of Curcuma wenyujin (C. wenyujin) volatile oil components in the treatment of lung diseases, including pulmonary fibrosis (PF), is gradually being recognized.. However, the anti-PF potential and underlying mechanisms of curcumenol (Cur), one of the Q-markers of C. wenyujin, remain underexplored.. Aim of the study: Gene expression profiles of PF were mined using an integrated bioinformatics approach to identify immune signature genes associated with disease development. SDS Page:Article Title: Macrophage extracellular traps as key mediators of scleral remodeling in myopia induced by hypoxia and activated platelets. Article Snippet: .. Samples were subjected to SDS-PAGE using 12.5%, 10%, or 7.5% gels (PG211, PG212, PG213, Epizyme Biotech, China) and transferred to polyvinylidene difluoride (PVDF) membranes (IPVH00010, Millipore, USA), which were subsequently blocked using Blocking Buffer (P0252, Beyotime, China) for 30 min at RT and incubated with primary antibodies: 1:1000 anti-citH3 antibody(ab219407, Abcam, UK), 1:1000 Collagen I/COL1A1 Rabbit pAb (A1352, Abclonal, China), 1:1000 Blocking Assay:Article Title: Macrophage extracellular traps as key mediators of scleral remodeling in myopia induced by hypoxia and activated platelets. Article Snippet: .. Samples were subjected to SDS-PAGE using 12.5%, 10%, or 7.5% gels (PG211, PG212, PG213, Epizyme Biotech, China) and transferred to polyvinylidene difluoride (PVDF) membranes (IPVH00010, Millipore, USA), which were subsequently blocked using Blocking Buffer (P0252, Beyotime, China) for 30 min at RT and incubated with primary antibodies: 1:1000 anti-citH3 antibody(ab219407, Abcam, UK), 1:1000 Collagen I/COL1A1 Rabbit pAb (A1352, Abclonal, China), 1:1000 Article Title: Macrophage extracellular traps as key mediators of scleral remodeling in myopia induced by hypoxia and activated platelets. Article Snippet: Unpermeabilized cells were blocked with 3% BSA (ST023, Beyotime, China) and incubated with 1:250 anti-citH3 antibody (ab219407, Abcam, UK) at 4◦C overnight. .. For other markers, cells were blocked with QuickBlock Blocking Buffer and incubated with 1:200 Incubation:Article Title: Macrophage extracellular traps as key mediators of scleral remodeling in myopia induced by hypoxia and activated platelets. Article Snippet: .. Samples were subjected to SDS-PAGE using 12.5%, 10%, or 7.5% gels (PG211, PG212, PG213, Epizyme Biotech, China) and transferred to polyvinylidene difluoride (PVDF) membranes (IPVH00010, Millipore, USA), which were subsequently blocked using Blocking Buffer (P0252, Beyotime, China) for 30 min at RT and incubated with primary antibodies: 1:1000 anti-citH3 antibody(ab219407, Abcam, UK), 1:1000 Collagen I/COL1A1 Rabbit pAb (A1352, Abclonal, China), 1:1000 Article Title: Macrophage extracellular traps as key mediators of scleral remodeling in myopia induced by hypoxia and activated platelets. Article Snippet: Unpermeabilized cells were blocked with 3% BSA (ST023, Beyotime, China) and incubated with 1:250 anti-citH3 antibody (ab219407, Abcam, UK) at 4◦C overnight. .. For other markers, cells were blocked with QuickBlock Blocking Buffer and incubated with 1:200 Bioprocessing:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Small Interfering RNA:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Generated:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Transfection:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Staining:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Bicinchoninic Acid Protein Assay:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Reverse Transcription:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Real-time Polymerase Chain Reaction:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Enzyme-linked Immunosorbent Assay:Article Title: Xueshuantong injection alleviates ischemic heart failure via targeting PFKP-mediated endothelial-to-mesenchymal transition Article Snippet: This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability.. This version will undergo additional copyediting, typesetting and review before it is published in its final form.. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. |